Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes

Sara Pusceddu, Roberto Buzzoni, Claudio Vernieri, Laura Concas, Sara Marceglia, Luca Giacomelli, Massimo Milione, Livia Leuzzi, Daniela Femia, Barbara Formisano, Vincenzo Mazzaferro, Filippo De Braud

Research output: Contribution to journalArticlepeer-review

Abstract

A bidirectional relationship seems to exist between diabetes mellitus and development of pancreatic tumors. Metformin, the most widely used drug in the treatment of Type 2 diabetes mellitus, has recently emerged as a potentially active agent in cancer chemoprevention and treatment. In this article, we discuss the potential correlation between glycemic status, administration of antiglycemic treatments, such as metformin or insulin, and prognosis of pancreatic neuroendocrine tumors patients treated with everolimus and octreotide, on the basis of existing evidence and our experience.

Original languageEnglish
Pages (from-to)1251-1260
Number of pages10
JournalFuture Oncology
Volume12
Issue number10
DOIs
Publication statusPublished - May 1 2016

Keywords

  • diabetes
  • metformin
  • mTOR inhibitor
  • pancreatic neuroendocrine tumors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes'. Together they form a unique fingerprint.

Cite this